A. Jang

Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2022, Molecular cancer therapeutics.

A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models

E. Butcher, B. Zabel, Serina Huang, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents

O. Vasiljeva, M. Belvin, W. Kavanaugh, 2021, Cancer Immunology Research.

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211)

D. Alberts, J. Moon, S. Wilczynski, 2006, International Journal of Gynecologic Cancer.